Diagnos Inc
XTSX:ADK
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Diagnos Inc
XTSX:ADK
|
34.3m CAD |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
28.5B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
12.1B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.7B USD |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
35.5B SEK |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
24.5B CNY |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
265B INR |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Diagnos Inc
Glance View
Diagnos, Inc. engages in the provision of healthcare technical services through the use of artificial intelligence (AI). The company is headquartered in Brossard, Quebec. The company went IPO on 2000-09-27. FLAIRE allows for quick modifying and developing of applications, such as CARA (Computer Assisted Retina Analysis). The firm markets CARA, a software platform which assists health specialists in the detection of diabetic retinopathy. CARA is an in-house hosted Web-based application that integrates fundus cameras with an image processing engine over an Internet connection. CARA offers payers and patients in automating the screening process. The CARA suite of applications allows an eye care specialist to clearly visualize both normal retinal landmarks, such as optic nerve, vascular system, macula, fovea, as well as pathological changes (exudates, hemorrhages, micro-aneurisms, neo-vascularization). The firm also offers data mining consulting services in the natural resources sector.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Diagnos Inc is -1 642.8%, which is below its 3-year median of -626.4%.
Over the last 3 years, Diagnos Inc’s Gross Margin has decreased from -49.8% to -1 642.8%. During this period, it reached a low of -1 642.8% on Oct 30, 2025 and a high of -38.4% on Dec 31, 2022.
